Johns Hopkins Medicine researchers supported clinical validation for the first FDA-cleared rapid urine test to aid diagnosis of invasive aspergillosis. The approach aims to shorten diagnostic delay relative to traditional workflows, a critical constraint in immunocompromised patients where early antifungal decisions can determine outcomes. For hospitals and clinical microbiology teams, the clearance introduces a new point-of-care diagnostic option, pending implementation details and evaluation in diverse patient populations.